Obesity Clinical Trials in Philadelphia

Showing 1-20 of 117 trials

Responsive Neurostimulation For Loss Of Control Eating

NCT03868670

The primary objective of this trial is to assess device function and safety, with secondary objectives including the feasibility.

Loss of Control EatingObesity, Morbid

University of Pennsylvania6 participantsStarted Apr 2019

Stanford, California, United States • Philadelphia, Pennsylvania, United States

RECRUITINGNA< 1 mile

Biobehavioral Reward Responses Associated With Consumption of Nutritionally Diverse Ultra-Processed Foods

NCT05437809

The changing food environment, with increasingly abundant ultra-processed food (UPF) options, may directly contribute to rising rates of obesity, though it is unknown which ingredients in UPF elevate their reinforcing nature in a way that may lead to overconsumption. The proposed study is the first to systematically examine differences in the rewarding characteristics of and physiological and metabolic responses to UPFs that are high in fat, refined carbohydrates (like sugar), or both. Understanding the biobehavioral underpinnings that enhance the reinforcing potential of ingredients in UPF (e.g., fat vs. refined carbohydrates) can inform novel intervention targets for the treatment of overeating and obesity.

ObesityOvereatingFood Addiction

Oregon Research Institute50 participantsStarted Feb 2023

Philadelphia, Pennsylvania, United States

COMPLETEDPHASE3< 1 mile

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

NCT06131437

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.

Obesity

Novo Nordisk A/S809 participantsStarted Nov 2023

Birmingham, Alabama, United States • Montgomery, Alabama, United States • Costa Mesa, California, United States +43 more locations

Responsive Neurostimulation For Loss Of Control Eating

Biobehavioral Reward Responses Associated With Consumption of Nutritionally Diverse Ultra-Processed Foods

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Obesity Trials in Other Cities

Partnering With WIC to Prevent Excessive Weight Gain in Pregnancy

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Telehealth Weight Loss Program for Breast Cancer Survivors

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Other Conditions in Philadelphia